Promoter-controlled infectivity-enhanced conditionally replicative adenoviral vectors for the treatment of gastric cancer

Journal of Gastroenterology

Volumn 40, Issue 1, 2005, Pages 31-42

  Ono, Hidetaka A ^a,b   Davydova, Julia G ^a   Adachi, Yasuo ^a   Takayama, Koichi ^a   Barker, Shannon D ^a   Reynolds, Paul N ^a   Krasnykh, Victor N ^c   Kunisaki, Chikara ^b   Shimada, Hiroshi ^b   Curiel, David T ^a   Yamamoto, Masato ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Conditionally replicative adenoviral vectors; Cytocidal effect; Fiber modification; Gastric cancer; Tumor specific promoter

Indexed keywords

ADENOVIRUS VECTOR; CONDITIONALLY REPLICATING ADENOVIRUS; CYCLOOXYGENASE 2; GASTRIN RELEASING PEPTIDE; LUCIFERASE; MIDKINE; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CHIMERA; CONTROLLED STUDY; CYTOMEGALOVIRUS; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; STOMACH CANCER; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS FIBER; VIRUS INFECTIVITY; VIRUS REPLICATION;

ADENOVIRIDAE; CELL LINE, TUMOR; CYCLOOXYGENASE 2; CYTOKINES; ENHANCER ELEMENTS (GENETICS); GASTRIN-RELEASING PEPTIDE; GASTROINTESTINAL AGENTS; GENE EXPRESSION REGULATION, VIRAL; GENETIC VECTORS; HUMANS; INTEGRINS; ONCOLYTIC VIROTHERAPY; PROMOTER REGIONS (GENETICS); PROTEINASE INHIBITORY PROTEINS, SECRETORY; PROTEINS; RECEPTORS, VIRUS; SERINE PROTEINASE INHIBITORS; STOMACH NEOPLASMS; TRANSCRIPTION, GENETIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VIRUS REPLICATION;

EID: 20444397790     PISSN: 09441174     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00535-004-1490-y     Document Type: Article

References (79)

1. Matsukura N, Ohgaki H. Stomach cancer. In: Stewart BW, Kleihues P, editors. World Cancer Rep IARC Press, Lyon, France: World Health Organization; 2003: P. 194-7.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94:153-6.
3. Tsuda H, Wada T, Ito Y, Uchida H, Dehari H, Nakamura K, et al. Efficient BMP2 gene transfer and bone formation of mesenchymal stem cells by a fiber-mutant adenoviral vector. Mol Ther 2003;7:354-65.
4. Bray F, Sankila R, Ferlay J, Parkin DM. Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer 2002; 38:99-166.
5. Curiel DT. The development of conditionally replicative adenoviruses for cancer therapy. Clin Cancer Res 2000;6:3395-9.
6. Alemany R, Balague C, Curiel DT. Replicative adenoviruses for cancer therapy. Nat Biotechnol 2000;18:723-7.
7. Kruyt FA, Curiel DT. Toward a new generation of conditionally replicating adenoviruses: Pairing tumor selectivity with maximal oncolysis. Hum Gene Ther 2002;13:485-95.
8. Kirn D, Martuza RL, Zwiebel J. Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nat Med 2001;7:781-7.
9. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996;274:373-6.
10. Ganly I, Kirn D, Eckhardt G, Rodriguez GI, Soutar DS, Otto R, et al. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res 2000;6:798-806.
11. Fueyo J, Gomez-Manzano C, Alemany R, Lee PS, McDonnell TJ, Mitlianga P, et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 2000;19: 2-12.
12. Goodrum FD, Ornelles DA. p53 Status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection. J Virol 1998;72:9479-90.
13. Hallenbeck PL, Chang YN, Hay C, Golightly D, Stewart D, Lin J, et al. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum Gene Ther 1999;10:1721-33.
14. Rodriguez R, Schuur ER, Lim HY, Henderson GA, Simons JW, Henderson DR. Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res 1997;57:2559-63.
15. Rothmann T, Hengstermann A, Whitaker NJ, Scheffner M, zur Hausen H. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J Virol 1998;72:9470-8.
16. Yu DC, Sakamoto GT, Henderson DR. Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy. Cancer Res 1999;59:1498-504.
17. Bilbao R, Gerolami R, Bralet MP, Qian C, Tran PL, Tennant B, et al. Transduction efficacy, antitumoral effect, and toxicity of adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir therapy of hepatocellular carcinoma: The woodchuck animal model. Cancer Gene Ther 2000;7:657-62.
18. Reynolds PN, Nicklin SA, Kaliberova L, Boatman BG, Grizzle WE, Balyasnikova IV, et al. Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivo. Nat Biotechnol 2001;19:838-42.
19. Bauerschmitz GJ, Nettelbeck DM, Kanerva A, Baker AH, Hemminki A, Reynolds PN, et al. The flt-1 promoter for transcriptional targeting of teratocarcinoma. Cancer Res 2002;62: 1271-4.
20. Adachi Y, Reynolds PN, Yamamoto M, Grizzle WE, Overturf K, Matsubara S, et al. Midkine promoter-based adenoviral vector gene delivery for pediatric solid tumors. Cancer Res 2000;60: 4305-10.
21. Adachi Y, Reynolds PN, Yamamoto M, Wang M, Takayama K, Matsubara S, et al. A midkine promoter-based conditionally replicative adenovirus for treatment of pediatric solid tumors and bone marrow tumor purging. Cancer Res 2001;61:7882-8.
22. Casado E, Gomez-Navarro J, Yamamoto M, Adachi Y, Coolidge CJ, Arafat WO, et al. Strategies to accomplish targeted expression of transgenes in ovarian cancer for molecular therapeutic applications. Clin Cancer Res 2001;7:2496-504.
23. Wesseling JG, Yamamoto M, Adachi Y, Bosma PJ, van Wijland M, Blackwell JL, et al. Midkine and cyclooxygenase-2 promoters are promising for adenoviral vector gene delivery of pancreatic carcinoma. Cancer Gene Ther 2001;8:990-6.
24. Nagi P, Vickers SM, Davydova J, Adachi Y, Takayama K, Barker S, et al. Development of a therapeutic adenoviral vector for cholangiocarcinoma combining tumor-restricted gene expression and infectivity enhancement. J Gastrointest Surg 2003;7:364-71.
25. Yamamoto M, Alemany R, Adachi Y, Grizzle WE, Curiel DT. Characterization of the cyclooxygenase-2 promoter in an adenoviral vector and its application for the mitigation of toxicity in suicide gene therapy of gastrointestinal cancers. Mol Ther 2001;3: 385-94.
26. Barker SD, Coolidge CJ, Kanerva A, Hakkarainen T, Yamamoto M, Liu B, et al. The secretory leukoprotease inhibitor (SLPI) promoter for ovarian cancer gene therapy. J Gene Med 2003;5: 300-10.
27. Barker SD, Dmitriev IP, Nettelbeck DM, Liu B, Rivera AA, Alvarez RD, et al. Combined transcriptional and transductional targeting improves the specificity and efficacy of adenoviral gene delivery to ovarian carcinoma. Gene Ther 2003;10:1198-204.
28. Inase N, Horita K, Tanaka M, Miyake S, Ichioka M, Yoshizawa Y. Use of gastrin-releasing peptide promoter for specific expression of thymidine kinase gene in small-cell lung carcinoma cells. Int J Cancer 2000;85:716-9.
29. Dmitriev I, Krasnykh V, Miller CR, Wang M, Kashentseva E, Mikheeva G, et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998;72:9706-13.
30. Kasono K, Blackwell JL, Douglas JT, Dmitriev I, Strong TV, Reynolds P, et al. Selective gene delivery to head and neck cancer cells via an integrin targeted adenoviral vector. Clin Cancer Res 1999;5:2571-9.
31. Wesseling JG, Bosma PJ, Krasnykh V, Kashentseva EA, Blackwell JL, Reynolds PN, et al. Improved gene transfer efficiency to primary and established human pancreatic carcinoma target cells via epidermal growth factor receptor and integrintargeted adenoviral vectors. Gene Ther 2001;8:969-76.
32. Bauerschmitz GJ, Lam JT, Kanerva A, Suzuki K, Nettelbeck DM, Dmitriev I, et al. Treatment of ovarian cancer with a tropism modified oncolytic adenovirus. Cancer Res 2002;62:1266-70.
33. Krasnykh VN, Mikheeva GV, Douglas JT, Curiel DT. Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism. J Virol 1996;70:6839-46.
34. Haviv YS, Blackwell JL, Kanerva A, Nagi P, Krasnykh V, Dmitriev I, et al. Adenoviral gene therapy for renal cancer requires retargeting to alternative cellular receptors. Cancer Res 2002;62:4273-81.
35. Kanerva A, Wang M, Bauerschmitz GJ, Lam JT, Desmond RA, Bhoola SM, et al. Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses. Mol Ther 2002;5:695-704.
36. Kanerva A, Mikheeva GV, Krasnykh V, Coolidge CJ, Lam JT, Mahasreshti PJ, et al. Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin Cancer Res 2002;8:275-80.
37. Kawakami Y, Li H, Lam JT, Krasnykh V, Curiel DT, Blackwell JL. Substitution of the adenovirus serotype 5 knob with a serotype 3 knob enhances multiple steps in virus replication. Cancer Res 2003;63:1262-9.
38. Adachi Y, Matsubara S, Muramatsu T, Curiel DT, Reynolds PN. Midkine promoter-based adenoviral suicide gene therapy to midkine-positive pediatric tumor. J Pediatr Surg 2002;37:588-92.
39. Horita K, Inase N, Miyake S, Formby B, Toyoda H, Yoshizawa Y. Progesterone induces apoptosis in malignant mesothelioma cells. Anticancer Res 2001;21:3871-4.
40. Morimoto E, Inase N, Mlyake S, Yoshizawa Y. Adenovirusmediated suicide gene transfer to small cell lung carcinoma using a tumor-specific promoter. Anticancer Res 2001;21:329-31.
41. Koshikawa N, Takenaga K, Tagawa M, Sakiyama S. Therapeutic efficacy of the suicide gene driven by the promoter of vascular endothelial growth factor gene against hypoxic tumor cells. Cancer Res 2000;60:2936-41.
42. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A 1998;95:2509-14.
43. Hsu KH, Lonberg-Holm K, Alstein B, Crowell RL. A monoclonal antibody specific for the cellular receptor for the group B coxsackieviruses. J Virol 1988;62:1647-52.
44. Russell SJ. Replicating vectors for cancer therapy: A question of strategy. Semin Cancer Biol 1994;5:437-43.
45. Kirn DH, McCormick F. Replicating viruses as selective cancer therapeutics. Mol Med Today 1996;2:519-27.
46. Onyx plans phase III trial of ONYX-015 for head and neck cancer. Oncologist 1999;4:432.
47. Heise C, Ganly I, Kim YT, Sampson-Johannes A, Brown R, Kirn D. Efficacy of a replication-selective adenovirus against ovarian carcinomatosis is dependent on tumor burden, viral replication and p53 status. Gene Ther 2000;7:1925-9.
48. Lamont JP, Nemunaitis J, Kuhn JA, Landers SA, McCarty TM. A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience). Ann Surg Oncol 2000;7:588-92.
49. Nemunaitis J, Ganly I, Khuri F, Arseneau J, Kuhn J, McCarty T, et al. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: A phase II trial. Cancer Res 2000;60:6359-66.
50. Kirn D. Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): Results of phase I and II trials. Expert Opin Biol Ther 2001;1:525-38.
51. Nemunaitis J, Khuri F, Ganly I, Arseneau J, Posner M, Vokes E, et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol 2001;19:289-98.
52. Nemunaitis J, O'Brien J. Head and neck cancer: Gene therapy approaches. Part II: Genes delivered. Expert Opin Biol Ther 2002; 2:311-24.
53. Reid T, Galanis E, Abbruzzese J, Sze D, Andrews J, Romel L, et al. Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial. Gene Ther 2001;8:1618-26.
54. Reid T, Galanis E, Abbruzzese J, Sze D, Wein LM, Andrews J, et al. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): Phase II viral, immunologic, and clinical end-points. Cancer Res 2002;62:6070-9.
55. Vasey PA, Shulman LN, Campos S, Davis J, Gore M, Johnston S, et al. Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J Clin Oncol 2002;20:1562-9.
56. Hamid O, Varterasian ML, Wadler S, Hecht JR, Benson A 3rd, Galanis E, et al. Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:1498-504.
57. Suzuki K, Alemany R, Yamamoto M, Curiel DT. The presence of the adenovirus E3 region improves the oncolytic potency of conditionally replicative adenoviruses. Clin Cancer Res 2002;8:3348-59.
58. Mulvihill S, Warren R, Venook A, Adler A, Randlev B, Heise C, et al. Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: A phase I trial. Gene Ther 2001;8:308-15.
59. Edwards SJ, Dix BR, Myers CJ, Dobson-Le D, Huschtscha L, Hibma M, et al. Evidence that replication of the antitumor adenovirus ONYX-015 is not controlled by the p53 and p14(ARF) tumor suppressor genes. J Virol 2002;76:12483-90.
60. Hecht JR, Bedford R, Abbruzzese JL, Lahoti S, Reid TR, Soetikno RM, et al. A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin Cancer Res 2003;9: 555-61.
61. Sze DY, Freeman SM, Slonim SM, Samuels SL, Andrews JC, Hicks M, et al. Dr. Gary J. Becker Young Investigator Award: Intraarterial adenovirus for metastatic gastrointestinal cancer: Activity, radiographic response, and survival. J Vasc Interv Radiol 2003;14:279-90.
62. Lee B, Choi J, Kim J, Kim JH, Joo CH, Cho YK, et al. Oncolysis of human gastric cancers by an E1B 55 kDa-deleted YKL-1 adenovirus. Cancer Lett 2002;185:225-33.
63. Lan KH, Kanai F, Shiratori Y, Okabe S, Yoshida Y, Wakimoto H, et al. Tumor-specific gene expression in carcinoembryonic antigen-producing gastric cancer cells using adenovirus vectors. Gastroenterology 1996;111:1241-51.
64. Tanaka T, Kanai F, Okabe S, Yoshida Y, Wakimoto H, Hamada H, et al. Adenovirus-mediated prodrug gene therapy for carcinoembryonic antigen-producing human gastric carcinoma cells in vitro. Cancer Res 1996;56:1341-5.
65. Lan KH, Kanai F, Shiratori Y, Ohashi M, Tanaka T, Okudaira T, et al. In vivo selective gene expression and therapy mediated by adenoviral vectors for human carcinoembryonic antigenproducing gastric carcinoma. Cancer Res 1997;57:4279-84.
66. Tanaka T, Kanai F, Lan KH, Ohashi M, Shiratori Y, Yoshida Y, et al. Adenovirus-mediated gene therapy of gastric carcinoma using cancer-specific gene expression in vivo. Biochem Biophys Res Commun 1997;231:775-9.
67. Ueda K, Iwahashi M, Nakamori M, Nakamura M, Yamaue H, Tanimura H. Enhanced selective gene expression by adenovirus vector using Cre/loxP regulation system for human carcinoembryonic antigen-producing carcinoma. Oncology 2000;59:255-65.
68. Ueda K, Iwahashi M, Nakamori M, Nakamura M, Matsuura I, Yamaue H, et al. Carcinoembryonic antigen-specific suicide gene therapy of cytosine deaminase/5-fluorocytosine enhanced by the cre/loxP system in the orthotopic gastric carcinoma model. Cancer Res 2001;61:6158-62.
69. Heideman DA, Snijders PJ, Craanen ME, Bloemena E, Meijer CJ, Meuwissen SG, et al. Selective gene delivery toward gastric and esophageal adenocarcinoma cells via EpCAM-targeted adenoviral vectors. Cancer Gene Ther 2001;8:342-51.
70. Zhang H, Wu J, Meng L, Shou CC. Expression of vascular endothelial growth factor and its receptors KDR and Flt-1 in gastric cancer cells. World J Gastroenterol 2002;8:994-8.
71. Rha SY, Noh SH, Kwak HJ, Wellstein A, Kim JH, Roh JK, et al. Comparison of biological phenotypes according to midkine expression in gastric cancer cells and their autocrine activities could be modulated by pentosan polysulfate. Cancer Lett 1997;118:37-46.
72. Aridome K, Takao S, Kaname T, Kadomatsu K, Natsugoe S, Kijima F, et al. Truncated midkine as a marker of diagnosis and detection of nodal metastases in gastrointestinal carcinomas. Br J Cancer 1998;78:472-7.
73. Uefuji K, Ichikura T, Mochizuki H, Shinomiya N. Expression of cyclooxygenase-2 protein in gastric adenocarcinoma. J Surg Oncol 1998;69:168-72.
74. Yamamoto H, Itoh F, Fukushima H, Hinoda Y, Imai K. Overexpression of cyclooxygenase-2 protein is less frequent in gastric cancers with microsatellite instability. Int J Cancer 1999; 84:400-3.
75. Kawabe A, Shimada Y, Uchida S, Maeda M, Yamasaki S, Kato M, et al. Expression of cyclooxygenase-2 in primary and remnant gastric carcinoma: comparing it with p53 accumulation, Helicobacter pylori infection, and vascular endothelial growth factor expression. J Surg Oncol 2002;80:79-88.
76. Dechecchi MC, Tamanini A, Bonizzato A, Cabrini G. Heparan sulfate glycosaminoglycans are involved in adenovirus type 5 and 2-host cell interactions. Virology 2000;268:382-90.
77. Dechecchi MC, Melotti P, Bonizzato A, Santacatterina M, Chilosi M, Cabrini G. Heparan sulfate glycosaminoglycans are receptors sufficient to mediate the initial binding of adenovirus types 2 and 5. J Virol 2001;75:8772-80.
78. Schnell MA, Zhang Y, Tazelaar J, Gao GP, Yu QC, Qian R, et al. Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. Mol Ther 2001;3:708-22.
79. Varnavski AN, Zhang Y, Schnell M, Tazelaar J, Louboutin JP, Yu QC, et al. Preexisting immunity to adenovirus in rhesus monkeys fails to prevent vector-induced toxicity. J Virol 2002;76:5711-9.